Daily Archives: January 6, 2018
Accuracy of the Enhanced Liver Fibrosis Test vs Fibrotest, Elastography and Indirect Markers in Detection of Advanced Fibrosis in Patients with Alcoholic Liver Disease
Alcohol is the leading cause of cirrhosis and liver-related mortality, but we lack serum markers to detect compensated disease. We compared the accuracy of the Enhanced Liver Fibrosis test (ELF), the FibroTest, liver stiffness measurements (made by tra… Continue reading
Posted in News
Comments Off on Accuracy of the Enhanced Liver Fibrosis Test vs Fibrotest, Elastography and Indirect Markers in Detection of Advanced Fibrosis in Patients with Alcoholic Liver Disease
Increasing Rates of Surgery for Patients With Non-Malignant Colorectal Polyps in the United States
Despite the availability of endoscopic therapy, many patients in the United States undergo surgical resection for non-malignant colorectal polyps. We aimed to quantify and examine trends in the use of surgery for non-malignant colorectal polyps in a na… Continue reading
Posted in News
Comments Off on Increasing Rates of Surgery for Patients With Non-Malignant Colorectal Polyps in the United States
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
A combination of infliximab and immunomodulators is the most efficacious treatment for Crohn’s disease (CD). Patients have the best outcomes when their serum concentrations of these drugs are above a determined therapeutic threshold. We performed a p… Continue reading
Posted in News
Comments Off on Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, or Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease